The main paper’s aim has been the growth factors urinary excretion study: transforming growth factor b1 (TGFb1), the vasculo-endothelium-derived growth factor – A (VEGF-A), and the interleukine – 1b (IL-1b) at the patients with the gouty nephropathy.
The Materials and Methods. The 59 men with the gout, gouty with the tubulo-interstitial nephritis, at the age from 40 to 50 years (e.g. the average age has been made up 42,2 ± 5,8 years or 508,2 ± 60,8 months) have been involved under the medical observation. So, all the medically observed sick men have already been divided into 2 main groups, according to the glomerular filtration rate (GFR) values: I group (n = 30) – GFR > 90 ml/min/1,73 m2 (e.g. the chronic kidney disease – CKD – the Stage 2 on K/DOQI, 2002); the II group (n = 29) – GFR – 60–89 ml/min/1,73 m2 (e.g. CKD – the 2 Stage). The podagra diagnosis has been met the EULAR, 2010 classification criteria. The gouty with the tubulo-interstitial nephritis diagnosis has been established, on the basis of the history, the clinical and laboratory studies. The control group has been consisted of the 20 healthy donors and the volunteers (e.g. men) at the age from 40 to 50 years (e.g. the average age has been made up 41,8 ± 4,6 years or 492,8 ± 48,6 months). Thus, the TGF-b1, VEGF-A, IL-b1 urinary excretion determination at the patients with the gouty tubulo-interstitial nephritis has been carried out and determined by the immune – enzyme analysis method.
The Results and Their Discussion. The growth factors urinary excretion determination: TGFb1 and VEGF-A at the patients with the gouty interstitial nephritis has been shown the following results. Significantly higher TGFb1 urinary excretion has been determined at the patients with the CKD 2 Stage (e.g. 30,4 ± 0,3 pg/ml, p < 0,05), having exceeded the patients with the CKD 1 Stage and the control group in 1,4 ± 0,2 (e.g. p < 0,05) time and 2,2 ± 0,3 (e.g. p < 0,05), respectively. The VEGF-A urinary excretion increase with the CKD progression has been determined. The VEGF-A higher level has been established at the patients with the gouty tubulo-interstitial nephritis with the CKD 2 Stage (e.g. 120,4 ± 4,4 pg/ml, p < 0,05).
The IL-1b urinary excretion higher level has been shown at the patients with the arthritic nephropathy with the CKD II Stage. The IL-1b content in the urine in 2,8 ± 0,2 (e.g. p < 0,05) has been exceeded the reference value, and in 1,4 ± 0,2 time – the indicator at the patients with the CKD 1 Stage at the patients in this group.
The Conclusions. It is taken its place the TGFb1, VEGF-A, and IL-1b urinary excretion increase with the CKD progression at the patients with the gouty tubulo-interstitial nephritis.
The work was submitted to International Scientific Conference «Fundamental and applied research in medicine», France (Paris), 14-21, October, 2012, came to the editorial office on 18.10.2012.